ATE497745T1 - Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren - Google Patents

Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren

Info

Publication number
ATE497745T1
ATE497745T1 AT05771439T AT05771439T ATE497745T1 AT E497745 T1 ATE497745 T1 AT E497745T1 AT 05771439 T AT05771439 T AT 05771439T AT 05771439 T AT05771439 T AT 05771439T AT E497745 T1 ATE497745 T1 AT E497745T1
Authority
AT
Austria
Prior art keywords
sustained release
progesterone receptor
release compositions
compositions containing
receptor modulators
Prior art date
Application number
AT05771439T
Other languages
English (en)
Inventor
Regine Sitruk-Ware
Yun-Yen Tsong
Original Assignee
Population Council Inc
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council Inc, Hra Pharma Lab filed Critical Population Council Inc
Application granted granted Critical
Publication of ATE497745T1 publication Critical patent/ATE497745T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
AT05771439T 2004-07-09 2005-07-08 Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren ATE497745T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58678304P 2004-07-09 2004-07-09
PCT/US2005/024474 WO2006010097A2 (en) 2004-07-09 2005-07-08 Sustained release compositions containing progesterone receptor modulators

Publications (1)

Publication Number Publication Date
ATE497745T1 true ATE497745T1 (de) 2011-02-15

Family

ID=35785781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05771439T ATE497745T1 (de) 2004-07-09 2005-07-08 Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren

Country Status (16)

Country Link
US (1) US8865200B2 (de)
EP (1) EP1768625B1 (de)
JP (2) JP5017109B2 (de)
KR (1) KR101229701B1 (de)
CN (1) CN101080205B (de)
AT (1) ATE497745T1 (de)
AU (1) AU2005265357B2 (de)
BR (1) BRPI0513141A (de)
CA (1) CA2573266C (de)
DE (1) DE602005026290D1 (de)
DK (1) DK1768625T3 (de)
ES (1) ES2360806T3 (de)
MX (1) MX2007000273A (de)
NZ (1) NZ552720A (de)
PT (1) PT1768625E (de)
WO (1) WO2006010097A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436428B1 (en) * 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US8399013B2 (en) 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US8062658B2 (en) * 2004-12-14 2011-11-22 Poly-Med, Inc. Multicomponent bioactive intravaginal ring
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
GB0613333D0 (en) * 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) * 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
WO2008007098A2 (en) * 2006-07-12 2008-01-17 Controlled Therapeutics (Scotland) Ltd. Drug delivery polymer with hydrochloride salt of clindamycin
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
ES2643318T3 (es) * 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
HRP20160689T1 (hr) * 2007-04-20 2016-07-15 Preglem S.A. Selektivni modulatori progesterona za tretman uterinog krvarenja
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
WO2009099586A2 (en) 2008-02-04 2009-08-13 Duramed Pharmaceuticals, Inc. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
HRP20161437T1 (hr) 2009-04-14 2017-02-10 Laboratoire Hra Pharma Postupak hitne kontracepcije
US20120129825A1 (en) 2009-04-14 2012-05-24 Andre Ulmann Method for on-demand contraception using levonorgestrel or norgestrel
US20120070476A1 (en) * 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
BR112012023281A2 (pt) * 2010-03-22 2016-05-17 Repros Therapeutics Inc composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal do mesmo farmaceuticamente aceitável do mesmo e de composição
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE202011110355U1 (de) * 2011-03-09 2014-01-15 Arstat, Inc. Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes
EP2545922A1 (de) 2011-07-12 2013-01-16 PregLem S.A. Behandlung von übermäßiger Monatsblutung im Zusammenhang mit Gebärmutterfibromen
IL215224A0 (en) * 2011-09-18 2012-02-29 Katz Daniel Dr Vaginal danazol combined with non steroidal anti inflammatory drugs (nsaids) compositions
WO2013098591A1 (es) * 2011-12-29 2013-07-04 Laboratorios Andrómaco S.A. Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres
FR2987271B1 (fr) * 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
EP2641602A1 (de) 2012-03-23 2013-09-25 PregLem S.A. Verfahren zur Behandlung gynäkologischer Leiden
EP2854763B1 (de) 2012-05-31 2018-09-26 Repros Therapeutics Inc. Formulierungen zur vaginalen abgabe von antiprogestinen
JP6200493B2 (ja) * 2012-09-28 2017-09-20 あすか製薬株式会社 無定形ウリプリスタール酢酸エステル
JP6343619B2 (ja) 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
FR2997627B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2999081B1 (fr) 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
JP6249790B2 (ja) 2013-01-29 2017-12-20 三菱鉛筆株式会社 シャープペンシル
MY181448A (en) 2013-04-10 2020-12-22 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
US20160296534A1 (en) 2013-04-11 2016-10-13 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
DE102014004388A1 (de) * 2014-03-26 2015-10-01 Angela Kayser Verfahren und System zum intravaginalen Verabreichen von Progesteron
JP6667450B2 (ja) * 2014-04-01 2020-03-18 ポリ−メッド インコーポレイテッド 避妊具及び関連した器具
EP2982352B1 (de) 2014-06-28 2018-10-03 Laboratorios Andrómaco S.A. Cervikalpessar mit einem umschlingungsdraht und progesteron mit verlängerter, verzögerter und kontinuierlicher freisetzung zur verhinderung von frühgeburten
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
EP3389632A4 (de) 2015-12-15 2019-11-06 Context Biopharma Inc. Amorphe onapristonzusammensetzungen und verfahren zur herstellung davon
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
AU2020384227B2 (en) 2019-11-12 2026-02-19 Poly-Med, Inc. Contraceptive medical devices
CN114073792A (zh) * 2020-08-11 2022-02-22 上海市生物医药技术研究院 含来曲唑的阴道环、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) * 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DE69702450T2 (de) * 1996-05-01 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer 21-substituierte progesteron derivate als antigestagene
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
US6358947B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
FR2822022B1 (fr) 2001-03-19 2005-11-04 Atofina Traitement pesticide des sols agricoles avec des composes soufres
CN1210079C (zh) * 2001-04-25 2005-07-13 上海市计划生育科学研究所 阴道环制剂及其应用
US7833545B2 (en) 2003-04-29 2010-11-16 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits

Also Published As

Publication number Publication date
US8865200B2 (en) 2014-10-21
WO2006010097A3 (en) 2006-08-10
WO2006010097A2 (en) 2006-01-26
JP2012040400A (ja) 2012-03-01
EP1768625B1 (de) 2011-02-09
AU2005265357B2 (en) 2011-04-07
AU2005265357A1 (en) 2006-01-26
KR20070044005A (ko) 2007-04-26
CA2573266C (en) 2011-11-08
PT1768625E (pt) 2011-04-18
BRPI0513141A (pt) 2008-04-29
CN101080205A (zh) 2007-11-28
CN101080205B (zh) 2011-10-12
CA2573266A1 (en) 2006-01-26
ES2360806T3 (es) 2011-06-09
KR101229701B1 (ko) 2013-02-05
EP1768625A2 (de) 2007-04-04
US20080199511A1 (en) 2008-08-21
JP2008505718A (ja) 2008-02-28
EP1768625A4 (de) 2008-07-09
JP5017109B2 (ja) 2012-09-05
DK1768625T3 (da) 2011-05-09
DE602005026290D1 (de) 2011-03-24
MX2007000273A (es) 2007-05-21
NZ552720A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
DK1768625T3 (da) Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
DK1983990T3 (da) Allosteriske A3-adenosin-receptormodulatorer
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
MX339797B (es) Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
UA94600C2 (en) Indole sulfonamide modulators of progesterone receptors
ECSP077131A (es) Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona
TW200606146A (en) Novel indole derivatives as selective androgen receptor modulators (SARMS)
PL1989218T3 (pl) Pochodne 17-fosforosteroidów użyteczne jako modulatory receptora progesteronowego
PE20151783A1 (es) Dispersion solida de un modulador selectivo de los receptores de progesterona
WO2006066011A3 (en) Compounds and compositions as modulators of steroidal receptors and calcium channel activities
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение
MX2007004861A (es) Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.
TW200604171A (en) Novel indole derivatives as selective androgen receptor modulators (SARMs)
DK1525215T3 (da) Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner
ECSP088147A (es) Moduladores del receptor de la cianopirrol-sulfonamida progesterona y los usos de los mismos
DK1732921T3 (da) Thiomidderivater som progesteronreceptormodulatorer
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
MD20150054A2 (ro) Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron
EA200702604A1 (ru) Производные бензофуранона как нестероидные модуляторы рецептора прогестерона
DE602005017577D1 (de) Selektive östrogen-rezeptor-modulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1768625

Country of ref document: EP